Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma
Table 2
NVG patient backgrounds according to treatment received. The majority of patients in the LEC group had stage 3 NVG and had previously received other treatments, such as adequate PRP, stand-alone anti-VEGF therapy, and PPV. Approximately half (41.2%) of patients that received frequent stand-alone anti-VEGF treatment had previously received repeated anti-VEGF injections.
Treatments
Anti-VEGF stand-alone therapy
Additional PRP
PPV
LEC
Number of treatments
17
89
28
32
Anti-VEGF combination therapy ()
—
49
15
3
Pre-treatment IOP (mmHg)
36.1 ± 12.5
36.1 ± 13.5
33.7 ± 13.9
35.0 ± 8.1
Criteria
Rubeosis group
1 (5.9%)
9 (10.1%)
4 (14.3%)
1 (3.1%)
Open-angle NVG group
10 (58.8%)
51 (57.3%)
12 (42.9%)
8 (25.0%)
Angle-closure NVG group
6 (35.3%)
12 (32.6%)
12 (42.9%)
23 (71.9%)
Previous treatment
Anti-VEGF stand-alone therapy
7 (41.2%)
1 (1.1%)
3 (10.7%)†
23 (71.9%)
PRP
17 (100.0%)
(44.9%)
(85.7%)
32 (100.0%)
PPV
4 (23.5%)
0 (0%)
0 (0%)
7 (21.9%)
LEC
1 (5.9%)
0 (0%)
0 (0%)
1 (3.1%)
Follow-up (pre-treatment, months)
2.5 ± 2.8 0.0 to 8.3
0.8 ± 3.0 0.0 to 22.3
3.2 ± 7.9 1.0 to 33.3
7.2 ± 11.5 0.0 to 48.8
Follow-up (post-treatment, months)
21.0 ± 19.7 4.1–53.2
25.4 ± 21.6 4.0–81.8
25.0 ± 14.3 5.1–56.0
24.5 ± 22.6 4.3–60.7
PRP, panretinal laser photocoagulation; PPV, pars plana vitrectomy, LEC, trabeculectomy with mitomycin C. Mean ± SD, Steel-Dwass test for PDR, for OIS.
